Market Cap 4.84B
Revenue (ttm) 441.54M
Net Income (ttm) 35.46M
EPS (ttm) N/A
PE Ratio 57.40
Forward PE 54.39
Profit Margin 8.03%
Debt to Equity Ratio 0.17
Volume 462,700
Avg Vol 932,684
Day's Range N/A - N/A
Shares Out 34.17M
Stochastic %K 47%
Beta 2.06
Analysts Strong Sell
Price Target $141.64

Company Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of s...

Industry: Medical Devices
Sector: Healthcare
Phone: 978 552 0900
Address:
200 Minuteman Road, Suite 302, Andover, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:53 PM
$TMDX: Current market context shows a strong bullish sentiment with the last close at $138.63. The RSI of 66.31 indicates that the stock is nearing overbought territory, suggesting a cautious approach. However, the price is above both the 30-day MA at $130.03 and the 50-day MA at $123.92, reinforcing a bullish trend. Directional bias is positive as the stock is trading closer to the 60-day high of $156.00, indicating potential upward momentum. The ATR of 8.82 suggests volatility, allowing for wider price movements. Suggested trade plan: - Entry: $139.00 - Stop Loss: $131.00 (approx. 5.8% risk) - Take Profit Targets: 1. $145.00 (approx. 4.3% gain) 2. $150.00 (approx. 7.9% gain) 3. $162.00 (approx. 16.8% gain) This plan offers a potential ROI of over 17% on the third target, aligning with the bullish outlook. https://privateprofiteers.com
0 · Reply
alnaqbi
alnaqbi Dec. 5 at 8:01 PM
$TMDX Waleed is shaping a legacy that will redefine the future of organ transplantation. The impact he’s making today won’t just elevate TransMedics it will leave a mark on the entire industry for generations to come. His vision, discipline, and relentless pursuit of innovation are building a future where saving lives becomes faster, safer, and globally accessible.
0 · Reply
alnaqbi
alnaqbi Dec. 5 at 7:26 PM
$TMDX TransMedics doesn’t seem to have much time to rest. With their ongoing European expansion, it looks like the next wave of growth will come from the GCC countries especially considering they already completed an organ transport procedure in a Saudi hospital less than a year ago. And with today’s news from the UAE highlighting a GCC-wide initiative to unify organ donation systems where TransMedics was directly involved the regional expansion now appears even more likely https://www.wam.ae/en/article/bn2764v-ministry-health-and-prevention-organises-gcc
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 9:00 PM
Enter: $TMDX Calls Strike Price: $145 Expiry Date: JAN 16 2026 Buy in Price: $9.20 - $11.70 Sell Price: $17.48 Profit : +90% (Turn every $1 into $1.90) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Twister8
Twister8 Dec. 4 at 8:35 PM
$TMDX added sub 135
0 · Reply
chrsc
chrsc Dec. 4 at 2:59 PM
$TMDX buy side should step back in here. healthy retrace.
0 · Reply
Doozio
Doozio Dec. 4 at 2:59 PM
$TMDX 🐒🍌🧠⏰♾️
1 · Reply
Wallstfan
Wallstfan Dec. 4 at 2:58 PM
$TMDX added under $134
1 · Reply
TriGuy8542
TriGuy8542 Dec. 4 at 2:43 PM
$TMDX just look at the Sox month pattern of higher low. It’s like the market wants to see 118 before doing another rip. So odd, but oh well, I’ll take the grind until Q4 ER
1 · Reply
Lambster2
Lambster2 Dec. 3 at 8:06 PM
$TMDX Do we get a third buy from Waleed? Wouldn't surprise me.
1 · Reply
Latest News on TMDX
3 Top Stocks to Buy in December

Dec 1, 2025, 7:45 PM EST - 4 days ago

3 Top Stocks to Buy in December

MELI VRTX


2 Strong Healthcare Stock Picks for Growth Investors

Nov 13, 2025, 8:15 AM EST - 22 days ago

2 Strong Healthcare Stock Picks for Growth Investors

HIMS


TransMedics: Growth Tailwinds Should Provide Upside In 2026

Oct 31, 2025, 11:54 AM EDT - 5 weeks ago

TransMedics: Growth Tailwinds Should Provide Upside In 2026


TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 10:56 PM EDT - 5 weeks ago

TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript


TransMedics Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 4:05 PM EDT - 5 weeks ago

TransMedics Reports Third Quarter 2025 Financial Results


2 Outstanding Healthcare Stocks to Buy and Hold for a Decade

Oct 8, 2025, 9:37 AM EDT - 2 months ago

2 Outstanding Healthcare Stocks to Buy and Hold for a Decade

HCA


TransMedics: I'm More Bullish Than Ever

Sep 22, 2025, 9:40 AM EDT - 2 months ago

TransMedics: I'm More Bullish Than Ever


TransMedics: Upcoming Trials Are Critical

Sep 16, 2025, 4:23 PM EDT - 2 months ago

TransMedics: Upcoming Trials Are Critical


TransMedics: Just Like The CEO, I'm Buying

Sep 3, 2025, 10:53 AM EDT - 3 months ago

TransMedics: Just Like The CEO, I'm Buying


TransMedics: Continued Strength Suggests Further Upside

Aug 1, 2025, 6:25 AM EDT - 4 months ago

TransMedics: Continued Strength Suggests Further Upside


Why TransMedics Stock Is Skyrocketing Today

Jul 31, 2025, 1:16 PM EDT - 4 months ago

Why TransMedics Stock Is Skyrocketing Today


TransMedics (TMDX) Q2 Revenue Jumps 38%

Jul 31, 2025, 5:16 AM EDT - 4 months ago

TransMedics (TMDX) Q2 Revenue Jumps 38%


TransMedics Group, Inc. (TMDX) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 12:28 AM EDT - 4 months ago

TransMedics Group, Inc. (TMDX) Q2 2025 Earnings Call Transcript


TransMedics Sees Its Earnings Soar

Jul 30, 2025, 5:06 PM EDT - 4 months ago

TransMedics Sees Its Earnings Soar


TransMedics Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 4 months ago

TransMedics Reports Second Quarter 2025 Financial Results


Why TransMedics Remains A Buy Into 2026

Jul 25, 2025, 11:57 AM EDT - 4 months ago

Why TransMedics Remains A Buy Into 2026


TransMedics: Q2 Analyst Estimates Will Fall Short

Jul 14, 2025, 12:27 AM EDT - 5 months ago

TransMedics: Q2 Analyst Estimates Will Fall Short


Is TransMedics Stock a Buy After Short-Seller Drama?

Jul 3, 2025, 7:00 PM EDT - 5 months ago

Is TransMedics Stock a Buy After Short-Seller Drama?


TransMedics: Extremely Undervalued And Extremely Innovative

May 21, 2025, 4:54 AM EDT - 7 months ago

TransMedics: Extremely Undervalued And Extremely Innovative


TransMedics to Present at Upcoming June Investor Conferences

May 20, 2025, 4:05 PM EDT - 7 months ago

TransMedics to Present at Upcoming June Investor Conferences


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:53 PM
$TMDX: Current market context shows a strong bullish sentiment with the last close at $138.63. The RSI of 66.31 indicates that the stock is nearing overbought territory, suggesting a cautious approach. However, the price is above both the 30-day MA at $130.03 and the 50-day MA at $123.92, reinforcing a bullish trend. Directional bias is positive as the stock is trading closer to the 60-day high of $156.00, indicating potential upward momentum. The ATR of 8.82 suggests volatility, allowing for wider price movements. Suggested trade plan: - Entry: $139.00 - Stop Loss: $131.00 (approx. 5.8% risk) - Take Profit Targets: 1. $145.00 (approx. 4.3% gain) 2. $150.00 (approx. 7.9% gain) 3. $162.00 (approx. 16.8% gain) This plan offers a potential ROI of over 17% on the third target, aligning with the bullish outlook. https://privateprofiteers.com
0 · Reply
alnaqbi
alnaqbi Dec. 5 at 8:01 PM
$TMDX Waleed is shaping a legacy that will redefine the future of organ transplantation. The impact he’s making today won’t just elevate TransMedics it will leave a mark on the entire industry for generations to come. His vision, discipline, and relentless pursuit of innovation are building a future where saving lives becomes faster, safer, and globally accessible.
0 · Reply
alnaqbi
alnaqbi Dec. 5 at 7:26 PM
$TMDX TransMedics doesn’t seem to have much time to rest. With their ongoing European expansion, it looks like the next wave of growth will come from the GCC countries especially considering they already completed an organ transport procedure in a Saudi hospital less than a year ago. And with today’s news from the UAE highlighting a GCC-wide initiative to unify organ donation systems where TransMedics was directly involved the regional expansion now appears even more likely https://www.wam.ae/en/article/bn2764v-ministry-health-and-prevention-organises-gcc
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 9:00 PM
Enter: $TMDX Calls Strike Price: $145 Expiry Date: JAN 16 2026 Buy in Price: $9.20 - $11.70 Sell Price: $17.48 Profit : +90% (Turn every $1 into $1.90) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Twister8
Twister8 Dec. 4 at 8:35 PM
$TMDX added sub 135
0 · Reply
chrsc
chrsc Dec. 4 at 2:59 PM
$TMDX buy side should step back in here. healthy retrace.
0 · Reply
Doozio
Doozio Dec. 4 at 2:59 PM
$TMDX 🐒🍌🧠⏰♾️
1 · Reply
Wallstfan
Wallstfan Dec. 4 at 2:58 PM
$TMDX added under $134
1 · Reply
TriGuy8542
TriGuy8542 Dec. 4 at 2:43 PM
$TMDX just look at the Sox month pattern of higher low. It’s like the market wants to see 118 before doing another rip. So odd, but oh well, I’ll take the grind until Q4 ER
1 · Reply
Lambster2
Lambster2 Dec. 3 at 8:06 PM
$TMDX Do we get a third buy from Waleed? Wouldn't surprise me.
1 · Reply
Twister8
Twister8 Dec. 3 at 2:55 PM
$TMDX 130-135 value range
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 3 at 2:02 PM
Enter: $TMDX Calls Strike Price: $155 Expiry Date: JAN 16 2026 Buy in Price: $10.82 - $13.50 Sell Price: $17.10 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Lambster2
Lambster2 Dec. 3 at 4:34 AM
$TMDX TransMedics (NASDAQ: TMDX) Buy (1) ESG Score: 61/100 Price Target: $170.00 Organ Transplant Volume and TMDX Aviation Flight Tracker THE TD COWEN INSIGHT We are tracking monthly U.S. heart, liver, and lung transplant volumes and TransMedics Aviation flights. TMDX has moved beyond the early innings of the Organ Care System (OCS) and National OCS Program (NOP) launches, so revenue performances have become levered to US transplant market trends and TransMedics Aviation flight runs, which should benefit from known annual seasonality 4Q tailwinds.
1 · Reply
Lambster2
Lambster2 Dec. 2 at 9:42 PM
$TMDX Got filled for 100 at 142 ah. 250 or bust. I can wait for it.
1 · Reply
Lambster2
Lambster2 Dec. 2 at 9:21 PM
$TMDX Crazy day. Will be adding for sure if we get 130s again.
0 · Reply
shitzushimazu
shitzushimazu Dec. 2 at 7:40 PM
$TMDX took profit! See you at least 90 points higher
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 6:02 PM
Morgan Stanley has adjusted their stance on TransMedics Group ( $TMDX ), setting the rating to Equal-Weight with a target price of 123 → 135.
0 · Reply
Twister8
Twister8 Dec. 2 at 3:59 PM
$TMDX due for a pullback, overbought.
1 · Reply
Digger75
Digger75 Dec. 2 at 3:13 PM
$TMDX hilarious hit the ask three times on a limit order won’t fill kept moving a penny above
1 · Reply
TriGuy8542
TriGuy8542 Dec. 2 at 2:58 PM
$TMDX Notes from the call Lung trials starting late Dec/Early Jan, last chance for docs to adopt OCS for lungs, company won't pursue any further innovation. Heart trials started. They think it could be as quick as 9 months, but stated 12-18 months originally. Still testing efficiency on plane, maybe no plane additions until 27 or 28. Kidney is 1.5x heart + liver + lung and 10k are unusable today (due to ischemic time) that will be accessible with OCS technology. 55-60% of kidney patients go on dialysis post transplant. Kidney utilization at all time low. CMS is ASKING TMDX for Kidney and don't forget a transplant surgeon leads CMS, Dr. Oz. Gen3 = big IOT and automation to boost margins further (will be incredible) Gerrardo didn't have any foot faults on his comments. Well done. All-in-all, great call and what I expected. If they can complete full heart study in 9-12 months then they should have guidance set to 20% for 2026.
1 · Reply
stephen19
stephen19 Dec. 2 at 12:47 PM
$TMDX Heading to 160++ still cheap shares !!!
0 · Reply
AutumnLee
AutumnLee Dec. 2 at 12:11 PM
$TMDX Morgan Stanley raised its price target to $135 from $123 and kept an Equal Weight rating. They see MedTech set up well into 2026 with supportive hospital spending and trough valuations creating a solid industry backdrop. TMDX cleared the 144.44 resistance and the downtrend line and is pushing into new highs with momentum picking up. As long as price holds above 144, upside magnets sit near the 1.272 extension around 158 and then the 1.618 extension up near 176.
1 · Reply